Detalhe da pesquisa
1.
Cardiovascular events and all-cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long-acting beta2-agonists.
Pharmacoepidemiol Drug Saf
; 31(8): 827-839, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320605
2.
Effect of long-acting ß2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients.
Pulm Pharmacol Ther
; 52: 1-6, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30077810
3.
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis.
COPD
; 12(5): 484-93, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25692310
4.
Chronic obstructive pulmonary disease and the risk of cardiovascular diseases.
Eur J Epidemiol
; 25(4): 253-60, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20191376
5.
Reflux disease, gastrointestinal ulcer or weight loss in patients with COPD.
COPD
; 7(3): 172-8, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20486815
6.
No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD.
Int J Chron Obstruct Pulmon Dis
; 15: 1945-1953, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32848380
7.
A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD.
Int J Chron Obstruct Pulmon Dis
; 15: 1955-1965, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32848381
8.
Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD.
Int J Chron Obstruct Pulmon Dis
; 15: 1935-1944, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32848379
9.
Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies.
NPJ Prim Care Respir Med
; 30(1): 53, 2020 12 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33277507
10.
No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study.
Sci Rep
; 10(1): 586, 2020 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31953521
11.
Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.
Int J Chron Obstruct Pulmon Dis
; 13: 1819-1831, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29910611
12.
Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.
Respir Med
; 143: 67-73, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30261995
13.
ß-Blockers in COPD: A Cohort Study From the TONADO Research Program.
Chest
; 153(6): 1315-1325, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29355547
14.
Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting ß2-agonist formoterol.
NPJ Prim Care Respir Med
; 27(1): 60, 2017 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-29061968
15.
Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.
Int J Chron Obstruct Pulmon Dis
; 12: 3329-3339, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29200840
16.
Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
Respir Med
; 122: 58-66, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27993292
17.
COPD and the risk of depression.
Chest
; 137(2): 341-7, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19801582
18.
Cancer risk in patients with chronic obstructive pulmonary disease.
Pragmat Obs Res
; 1: 15-23, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-27774005